Patents Assigned to Transgenic Inc.
  • High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification
    Patent number: 8883972
    Abstract: The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: November 11, 2014
    Assignees: Transgenic Inc., President, National Cancer Center
    Inventors: Hiroshi Nose, Tomoyo Hashiguchi, Masaya Ono, Tesshi Yamada, Setsuo Hirohashi
  • Trap vectors and gene trapping method by using the same
    Patent number: 8722408
    Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: May 13, 2014
    Assignee: Transgenic Inc.
    Inventors: Ken-ichi Yamamura, Kimi Araki
  • Trap vectors and gene trapping by using the same
    Patent number: 7312075
    Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: December 25, 2007
    Assignee: Transgenic Inc.
    Inventors: Ken-ichi Yamamura, Kimi Araki
  • Transgenically produced Antithrombin III
    Patent number: 6441145
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 27, 2002
    Assignee: Genzyme Transgenics, Inc.
    Inventors: Paul DiTullio, Harry Meade, Edward S. Cole